talizumab
oleclumab
antiantibody
sonepcizumab
immunoprotective
drozitumab
intrabody
tucotuzumab
elotuzumab
durvalumab
adebrelimab
ocrelizumab
robatumumab
antimonoclonal
mapatumumab
conatumumab
antipolyvalent
siltuximab
idiospecific
atezolizumab
teplizumab
etesevimab
ozoralizumab
immunoprotection
afasevikumab
polyvalent
adjuvant
antinucleoside
dorlixizumab
antiplasma
heteroclitic
olendalizumab
pancytokeratin
monospecific
chromobody
polyantibody
microlymphocytotoxicity
panitumumab
immunoadsorbent
immunogen
matuzumab
antiantitoxin
agglutin
lintuzumab
bispecific
agonistic monoclonal antibody
presentation
antigenomic
teclistamab
belimumab